Aethlon Medical.
Company
- Reports this week
- 0
- Active events
- 0
- Connections
- 28
What's happening
One to three months ago
Gone quiet
No new reports in 90+ days-
Aethlon Medical filed required reports with the SEC, traded on Nasdaq, and was discussed on financial blogs like MarketBeat.Some support2 reports
-
Aethlon Medical received two Breakthrough Device Designations from the FDA and is moving forward with clinical trials.Some support1 report
-
Aethlon Medical received CDSCO approval to initiate an oncology trial and is running a trial in Australia.Some support5 reports1 development inside
-
Aethlon Medical is conducting an oncology study in Australia, treating a participant at Royal North Shore Hospital.Some support1 report
-
Aethlon Medical received U.S. Food and Drug Breakthrough Device status for its device.Some support1 report
-
Aethlon Medical announced on September 4, 2025, that it had an effective registration statement with the SEC, with Maxim Group acting as the placement agent.Some support1 report
-
Aethlon Medical monitors the Bundibugyo Ebola outbreak in DRC while its stock price reacts to global health crisis news.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Aethlon Medical this week
News at the entities that move Aethlon Medical most-
FDA StructuralFDA conducted surprise raids and inspections in Bihar state, directed by state government officials.Moves Aethlon Medical
-
Nasdaq StructuralVMware's stock performance was tracked on the Nasdaq exchange on October 25, 2026.Moves Aethlon Medical
-
SEC StructuralCNBC reports on FED rate decisions and their impact on the Main Street economy and SEC yields.Moves Aethlon Medical
-
Securities and Exchange Commission StructuralBlackRock filed disclosures with the SEC regarding the iShares 0-3 Month Treasury Bond ETF.Moves Aethlon Medical
-
University of Sydney StructuralMerck and Moderna funded an Australian-led clinical trial involving the University of Sydney.Moves Aethlon Medical
-
University of California OperationalResearchers from UC and Oak Ridge National Laboratory collaborated on a study using CCI as a spectral trait phenotype.Moves Aethlon Medical
Connections
The 11 strongest of 28, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
The FDA grants formal Breakthrough Device designations to Aethlon Medical products.
-
SEC Structural
Aethlon Medical operates under the mandatory reporting and oversight requirements of the U.S. Securities and Exchange Commission.
-
Nasdaq Structural
Aethlon Medical is listed and trades its shares on the Nasdaq stock exchange.
-
Securities and Exchange Commission Structural
Aethlon Medical operates as a company under the regulatory purview of the Securities and Exchange Commission.
-
University of Sydney Structural
University of Sydney provides laboratory support to Aethlon Medical for clinical trials.
-
University of California Operational
The entities collaborated on peer-reviewed research findings.
-
Uganda Transactional
a deal or exchange
-
Royal North Shore Hospital Operational
Aethlon Medical provides treatment services to participants at Royal North Shore Hospital.
Show all 11 connections
-
San Diego Shared context
Aethlon Medical operates within the geographical context of San Diego.
-
MarketBeat Mentioned together
MarketBeat features Aethlon Medical in its financial screener and articles.
-
Zaire Shared context
Aethlon Medical operates in the region of Zaire, specifically monitoring the Bundibugyo Ebola outbreak in the DRC.
History
Events by the month they beganAugust 2026
1 eventJuly 2026
1 eventJune 2026
7 events- Aethlon Medical's Hemopurifier® device is being used for treating Long COVID and CAC.
- Aethlon Medical received two Breakthrough Device Designations from the FDA and is moving forward with clinical trials.
- Aethlon Medical received CDSCO approval to initiate an oncology trial and is running a trial in Australia.
- Aethlon Medical is conducting an oncology study in Australia, treating a participant at Royal North Shore Hospital.
- Aethlon Medical received U.S. Food and Drug Breakthrough Device status for its device.
- Aethlon Medical announced on September 4, 2025, that it had an effective registration statement with the SEC, with Maxim Group acting as the placement agent.
- Aethlon Medical monitors the Bundibugyo Ebola outbreak in DRC while its stock price reacts to global health crisis news.